Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

The number of lung cancer diagnoses amongst people who have never smoked is increasing globally, according to the World ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...

This progress is mostly because of steady declines in the four most common types of cancer—breast, colorectal, lung, and prostate. Not sure how death rate is different ... The screening test for ...

However, metformin did not protect Black patients against squamous cell carcinoma specifically ... protective agent against non-melanoma skin cancer, especially after adjusting for medications ...

2Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York. Search for other works by this author on: ...

second primary invasive nonbreast cancer, or death — no. (%) 245 (33.0) 156 (21.0) 7-Year event-free survival — % (95% CI) 66.2 (62.5–69.8) 79.8 (76.8–82.8) Unstratified hazard ratio for ...

can better predict lung cancer survival at the point of diagnosis, which could inform treatment decisions and potentially reduce the risk of the cancer returning or spreading. In research ...